Atopic dermatitis is a chronic, inflammatory skin condition characterized by persistent dryness, itching, and skin barrier dysfunction. It can significantly impact quality of life, affecting sleep, comfort, and overall well-being.
At Rejuvenation Dermatology, our Atopic Dermatitis Clinical Trials program is designed to advance treatment options through regulated, ethically conducted research while providing patients access to emerging therapies that may not yet be commercially available.
Integrated within our dermatology clinics across Canada, our clinical trials offer expert medical oversight, detailed skin assessments, and study-related care at no cost. By collaborating with leading pharmaceutical sponsors, our physicians contribute to the development of safer, more targeted therapies for atopic dermatitis.
Participation in clinical trials provides eligible patients with structured care, ongoing monitoring, and the opportunity to play a meaningful role in advancing the future of dermatologic treatment.
STUDY INFO:
A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD).
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
If you are interested in joining this study, please click here.
STUDY INFO:
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis.
If you are interested in joining this study, please click here.
STUDY INFO:
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777.
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years).
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment.
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment.
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
STUDY INFO:
CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness.
If you are interested in joining this study, please click here.
EVIDENCE DRIVES BETTER ECZEMA CARE
We believe effective atopic dermatitis treatment must be rooted in science. Our clinical trials are designed to evaluate emerging therapies under strict regulatory conditions, generating high-quality data that improves patient outcomes and treatment standards.
RESEARCH INTEGRATED INTO REAL CLINICAL PRACTICE
Clinical trials are embedded within our dermatology clinics, ensuring patients receive care in a familiar, physician-led environment. Our dermatologists understand the chronic, relapsing nature of atopic dermatitis and tailor care accordingly.
ETHICS ARE NON-NEGOTIABLE
Every atopic dermatitis trial is reviewed by an independent ethics board prior to enrollment. Patients are fully informed, carefully screened, and monitored throughout the study with safety protocols that meet and exceed regulatory requirements.
STANDARDIZED, NATIONAL EXECUTION
Our multi-site research network operates under centralized oversight, standardized training, and consistent protocols. This ensures high-quality data, efficient enrollment, and dependable outcomes across all participating locations.
Clinical research at Rejuvenation Dermatology is driven by a commitment to advance patient care through evidence-based medicine. Through participating in regulated clinical trials, the organization helps to shape development of safer, more effective dermatologic treatments while ensuring patients receive care that meets the highest ethical and scientific standards.
Participation in clinical research enables Rejuvenation physicians to remain at the forefront of dermatologic innovation and provides patients with access to therapies that may not yet be commercially available.
DERMATOLOGY-LED RESEARCH
All clinical trials are conducted under the supervision of board-certified dermatologists with extensive experience in managing atopic dermatitis. Patients benefit from expert care at every stage of participation.
NATIONAL REACH, LOCAL CARE
With multiple research sites across Canada, we combine the scale required for high-quality clinical research with the personalized care of local dermatology clinics, delivering consistency without sacrificing patient experience.
SAFETY FIRST, ALWAYS
Patient safety is our top priority. Strict eligibility criteria, continuous monitoring, and adherence to Good Clinical Practice (GCP) standards ensure a safe and controlled research environment.
RELIABLE DATA, TRUSTED BY SPONSORS
Our structured processes and experienced teams allow us to deliver consistent, high-quality data. This level of rigor ensures a seamless experience for both sponsors and participants.
RESEARCH WITH REAL IMPACT
Participation in atopic dermatitis clinical trials contributes to therapies that may shape future standards of care. Patients play an active role in advancing treatment options for chronic eczema.
Clinical trials may include mild, moderate, or severe atopic dermatitis, depending on the study criteria. Some trials focus on patients who have not responded well to standard treatments.
No. Study-related care, assessments, and investigational treatments are provided at no cost to eligible participants.
This depends on the specific study protocol. Some trials require a washout period, while others may allow certain ongoing treatments. Your eligibility and treatment plan will be reviewed during screening.
ACNE CLINICAL TRIALS | CLINICAL TRIALS CANADA | REJUVENATION DERMATOLOGY
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
